Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from LLY

Lilly Unites With ImmunoGen In ADC Deal Worth Up To $1.7B

ImmunoGen Inc (NASDAQ: IMGN) has

FDA AdComm Votes Against Lilly's Lung Cancer Drug, Sintilimab

FDA AdComm Votes Against Lilly's Lung Cancer Drug, Sintilimab

The FDA advisory committee voted against the full approval of Eli Lilly And Co's (NYSE: LLY) lung cancer treatment over concerns that the clinical trial was conducted only in China and that its results did not apply to U.S. patients.

4 Top Dividend Growth Stocks to Add to Your Watchlist

4 Top Dividend Growth Stocks to Add to Your Watchlist

Dividend investing is an effective way of generating income with limited concern about market volatility. So, investors looking to assure a consistent flow of income, along with capital appreciation, could consider adding quality dividend stocks Microsoft (MSFT), Eli Lilly (LLY), Zoetis (ZTS), and The TJX (TJX) to their watchlists. These…

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

The Daily Biotech Pulse: AstraZeneca Q4 Gets COVID Boost, Seagen Plunges On Earnings, Adcom Test Awaits Lilly

Here's a roundup of top developments in the biotech space over the last 24 hours:

Eli Lilly Q4 Earnings Beat Estimates On Higher Demand For Trulicity, COVID-19 Therapies; Reaffirms FY22 Guidance

Eli Lilly And Co (NYSE: LLY) has

Lilly To Inject $1B In New Manufacturing Facility In North Carolina, US

Eli Lilly And Co (NYSE: LLY)

Eli Lilly Plans To Invest €400M In Manufacturing Facility In Ireland: Report

Eli Lilly And Co (NYSE: LLY) plans to invest more than €400 million into a new manufacturing facility in Limerick, Ireland, according to a

inkl

Read news from The Economist, FT, and more,
with one subscription

Eli Lilly Expects FDA Rejection For Expanded Use Baricitinib For Eczema

Eli Lilly Expects FDA Rejection For Expanded Use Baricitinib For Eczema

Based on top-line efficacy results from two pivotal Phase 3 trials Eli Lilly And Co (NYSE: LLY) has decided to

FDA Rescinds Authorization For Regeneron, Eli Lilly COVID-19 Antibody Treatments: Here's Why

FDA Rescinds Authorization For Regeneron, Eli Lilly COVID-19 Antibody Treatments: Here's Why

Antibody treatments made by Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Eli Lilly And Co (NYSE: LLY) are not likely to work against the Omicron variant of COVID-19 and their emergency use authorization has been rescin

If You Invested $1000 In This Stock 5 Years Ago, Here's How Much You Would Have Today

If You Invested $1000 In This Stock 5 Years Ago, Here's How Much You Would Have Today

Eli Lilly (NYSE:LLY) has outperformed the market over the past 5 years by 12.31% on an annualized basis.

Expert Ratings For Eli Lilly

Expert Ratings For Eli Lilly

Over the past 3 months, 7 analysts have published their opinion on Eli Lilly (NYSE:LLY) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Abbisko, Lilly Ink Licensing Pact For Cardiometabolic Diseases

Abbisko, Lilly Ink Licensing Pact For Cardiometabolic Diseases

Abbisko Therapeutics has entered into a worldwide collaboration and exclusive licensing agreement with Eli Lilly And Co (NYSE: LLY) for novel molecules against an

1 … 11 12 13 14

Organisations

Eli Lilly And Co

Regeneron Pharmaceuticals Inc

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Topics

inkl

Read news from The Economist, FT, and more,
with one subscription

Places

389,075 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play